Ascoril expectorant (Bromhexine,Guaifenesin,Salbutamol)

As part of the combined therapy of acute and chronic bronchopulmonary diseases, accompanied by the formation of a difficult-to-separate viscous secretion:

bronchial asthma,

tracheobronchitis,

obstructive bronchitis,

pneumonia,

emphysema of the lungs,

whooping cough,

pneumoconiosis,

tuberculosis of the lungs.

Inside, 3 times a day. Adults and children over 12 years — 10 ml (2 teaspoons), children under 6 years — 5 ml (1 hour).spoon), from 6 to 12 years — 5-10 ml (1-2 hours).spoons).

Shake well before use.

hypersensitivity to the components of the drug,

tachyarrhythmia, myocarditis,

heart defects,

decompensated diabetes mellitus,

thyrotoxicosis,

glaucoma,

liver or kidney failure,

peptic ulcer of the stomach and duodenum in the acute stage,

pregnancy,

lactation period.

With caution it is prescribed to patients with diabetes mellitus, gastric ulcer and duodenal ulcer in remission.

Rarely-when used in high doses, sometimes there is headache, dizziness, increased nervous excitability, sleep disturbance, drowsiness, tremor, convulsions, nausea, vomiting, diarrhea, exacerbation of gastric ulcer and duodenal ulcer, palpitations, possible urine staining in pink, allergic reactions (rash, urticaria), collapse, bronchospasm.

Symptoms: increased manifestations of side effects, with the exception of dose-dependent allergic reactions.

Treatment: symptomatic therapy.

The combined drug has a bronchodilator, expectorant and mucolytic effect.

Bromhexine - mucolytic agent. It has an expectorant effect, improves the discharge of sputum.

Guaifenesin - mucolytic agent, reduces the surface tension of the structures of the bronchopulmonary apparatus, stimulates the secretory cells of the bronchial mucosa that produce neutral polysaccharides, depolymerizes acidic mucopolysaccharides, reduces the viscosity of sputum, facilitates the removal of sputum and promotes the transition of unproductive cough to productive.

Salbutamol — bronchodilator remedy stimulates the beta₂- adrenoreceptors of the bronchi, blood vessels and myometrium. Prevents or eliminates bronchial spasm, reduces resistance in the respiratory tract, increases the vital capacity of the lungs. Causes dilation of the coronary arteries, does not reduce blood pressure.

Bromhexine. When taken orally, it is almost completely (99%) absorbed into the gastrointestinal tract within 30 minutes. Bioavailability is low (the effect of primary passage through the liver). Penetrates through the placental barrier and BBB. In the liver, it undergoes demethylation and oxidation, and is metabolized to pharmacologically active ambroxol. T_1/2 - 15 h (due to slow reverse diffusion from the tissues). It is excreted by the kidneys. With CRF, the excretion of metabolites is disrupted. With repeated use, it can accumulate.

Guaifenesin. Absorption from the gastrointestinal tract is rapid (25-30 minutes after ingestion). T_1/2 - 1 h. Penetrates into tissues containing acidic mucopolysaccharides. Approximately 60% of the administered drug is metabolized in the liver. It is excreted by the lungs (with sputum) and kidneys both in unchanged form and in the form of inactive metabolites.

Salbutamol. When ingested, the absorption is high. Food intake reduces the rate of absorption, but does not affect bioavailability. The binding to plasma proteins is 10%. Penetrates through the placenta. It undergoes presystemic metabolism in the liver and intestinal wall, and is inactivated to 4-o-sulfate ether by phenolsulfotransferase. T_1/2 - 3.8-6 hours. It is excreted by the kidneys (69-90%), mainly in the form of an inactive phenol sulfate metabolite (60%) for 72 hours and with bile (4%). The bioavailability of orally administered salbutamol is about 50%.

• Expectorant combined agent [Secretolytics and stimulators of motor function of the respiratory tract in combinations]

Other betas₂- adrenomimetic agents and theophylline enhance the effect of salbutamol and increase the likelihood of side effects.

Ascoril expectorant is not prescribed simultaneously with drugs containing codeine and other antitussive agents, since this makes it difficult to discharge liquefied sputum.

The Ascoril expectorant bromhexin, which is part of the drug, promotes the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) into the lung tissue.

It is not recommended to use the drug Ascoril expectorant simultaneously with non-selective beta-adrenoceptor blockers, such as propranolol.

The Ascoril expectorant salbutamol, which is part of the drug, is not recommended for patients who receive MAO inhibitors.

Diuretics and corticosteroids increase the hypokalemic effect of salbutamol.

It is not recommended to take at the same time with the drug Ascoril expectorant alkaline drink.

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

Syrup. 100 or 200 ml each in a dark-colored plastic bottle with a screw-on aluminum lid with first-opening control, on which a white plastic measuring cap or a transparent plastic measuring cap with the "G" logo and multi-colored risks (green for 2.5 ml, yellow for 5 ml and red for 10 ml) is fixed. Each bottle is placed in a cardboard box.

Contraindicated in pregnancy. Breastfeeding should be discontinued for the duration of treatment.

According to the recipe.

R05C Expectorants, other than combinations with antitussives

• A15-A19 Tuberculosis
• A16 Respiratory tuberculosis, not confirmed bacteriologically or histologically
• A37 Whooping cough
• J18 Pneumonia without specifying the causative agent
• J40 Bronchitis, not specified as acute or chronic
• J43 Emphysema
• J44 Other chronic obstructive pulmonary disease
• J45 Asthma
• J64 Pneumoconiosis, unspecified
• R09. 3 Sputum

Transparent orange-colored viscous liquid with a specific smell.